Skip to main content

Sjogrens

anita
@docdhanrajani
@RheumNow Abstract #2483 Pediatric Sjögren’s lacks validated clinical trial endpoints, limiting treatment research. This study developed a prioritized, 8-domain patient-centered endpoint for N-of-1 trials, bridging objective disease activity and lived symptom burden. #ACR26
Daric Mueller, PA-C
@rheumPAC
(2/2) LB22 Both DAZ arms with similar AEs compared to placebo group Signal for symptom response at 4W? Improved pt reported sicca outcomes with 1500mg Q4W dose vs placebo @RheumNow #ACR26
Daric Mueller, PA-C
@rheumPAC
(1/2)#ACRBest Dazodalibep (DAZ) for systemically active SjD Ph3 top line results! LB22 648 pts IV DAZ 1500mg Q4W or 3000mg Q12W vs placebo Signf improved ESSDAI in both DAZ arms @ 48W. ESDAI differences vs placebo -1.8 for 1500mg Q4W, -1.4 for 3000mg Q12W @RheumNow #ACR26
Janet Pope
@Janetbirdope
#FcRn #efigartigimod + #RCT in #IMNM & #DM #LB24 But 😞 #SjD RCT stopped 🛑 for #futility We will have niche Rx for many rare #SARDs I think over next few yrs #ACR26 @ACRheum @RheumNow
sheila
@RHEUMarampa
OASIZ-301 Trial- Dazodalibep for SjD Both DAZ arms (3000mg & 1500mg) demonstrated sign. improvements in ESSDAI at wk 48 vs PBO DAZ arms also met key sec endpts - including sign. improved ESSPRI/DASPRI dryness domains w/1500mg Both arms safe & welltolerated @RheumNow #ACR26 LB22 https://t.co/GjnDCWkMG7
Adela Castro
@AdelaCastro222
Lip biopsy for Sjogren's disease diagnosis? Great debate at #ACR26 @RheumNow
Audrey Gibson
@Gibson_RheumPAC
Dörner et al: The NEPTUNUS extension examines longer-term ianalumab treatment in Sjögren's disease after positive phase 3 trials. Durability, safety and sustained disease control are the questions to watch. @rheumnow #ACR2026 Abstract#LB14
Audrey Gibson
@Gibson_RheumPAC
Could familiar DMARDs become a treatment strategy for Sjögren's? The NECESSITY trial reports efficacy with HCQ + leflunomide and HCQ + MMF combinations. An intriguing potential option while targeted treatment development continues. #LB15 @RheumNow #ACR26
Audrey Gibson
@Gibson_RheumPAC
Sjögren's treatment is entering a new era! Long-term NEPTUNUS extension data examine durability and safety of ianalumab, a BAFF-R–targeting antibody, Phase 3 results. Dörner et al. | #LB14 @RheumNow #ACR26
Dr. John Cush
@RheumNow
#ACR26 – Big Pharma Brings Its Biggest Readouts to Orlando ACR Convergence 2026 runs November 6–11 in Orlando, and the major companies will be presenting their highlight trials this week. Phase 3 results in Sjögren's and gout headline the late-breaking orals, while plenaries https://t.co/WPYb7AkoI2
×